Praxis Precision Medicines Participates in Investor Events
BOSTON – Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a forward-thinking clinical-stage biopharmaceutical company known for its innovative approach to addressing central nervous system (CNS) disorders. With a mission centered around translating genetic insights into effective therapies, Praxis has made significant strides in the field. This month, the company has announced its participation in two key investor conferences, showcasing its commitment to engaging with stakeholders and advancing its initiatives.
Upcoming Events in April
The first of the two events is the renowned 24th Annual Needham Virtual Healthcare Conference, where Praxis management will present a comprehensive corporate overview. Scheduled for Monday, April 7, this virtual event will kick off at 11:00 a.m. EDT. Participants can expect a detailed webcast of the session, which will provide valuable insights into the company’s current projects and strategic vision.
Details of the Needham Conference Participation
During the Needham conference, attendees will have the unique opportunity to hear directly from Praxis leadership. The webcast will cover the company’s advancements in developing therapies that target neuronal excitation-inhibition imbalances—a crucial aspect of treating CNS disorders. Interested individuals should keep an eye on the Events & Presentations page for access to the live session.
Engagement at the Piper Sandler Symposium
In addition to the Needham Conference, Praxis will also feature prominently at the Piper Sandler Spring Biopharma Symposium, taking place on April 17 at One Boston Place. This event serves as a significant platform for the biopharmaceutical community to gather, allowing Praxis to connect with other leaders and potential investors.
Opportunity for One-on-One Meetings
Praxis will facilitate one-on-one meetings during both conferences, creating an excellent opportunity for investors to gain deeper insight into the company’s pipeline and future directions. Interested parties are encouraged to reach out to their respective Needham and Piper Sandler representatives to arrange these discussions.
Webcast Replays and Future Engagements
For those unable to attend the live events, Praxis will provide access to replays of the webcasts. These will be available on the company's website under the Investors + Media section, ensuring that stakeholders can stay informed about the latest developments and presentations from the organization.
About Praxis Precision Medicines
Founded on the principle of leveraging genetic insights, Praxis Precision Medicines is dedicated to the discovery and development of innovative therapies for CNS disorders. With a focus on neurological diseases linked to excitation-inhibition imbalance, the company utilizes advanced platforms, such as Cerebrum™ and Solidus™, to explore treatments for both rare and more common conditions. The company boasts a diversified pipeline, including several clinical-stage product candidates aimed at addressing critical health challenges.
For further details about Praxis’s initiatives and to explore their full range of therapies, visit www.praxismedicines.com. Stay updated on their ongoing activities and research efforts through their social media channels on platforms like Facebook, Instagram, LinkedIn, and Twitter/X.
Frequently Asked Questions
1. What is the focus of Praxis Precision Medicines?
Praxis focuses on developing therapies for CNS disorders, particularly aiming to restore balance in neuronal excitation and inhibition.
2. When are the upcoming conferences that Praxis is participating in?
Praxis will participate in the Needham Virtual Healthcare Conference on April 7 and the Piper Sandler Spring Biopharma Symposium on April 17.
3. Will there be opportunities for investors to meet with Praxis management?
Yes, there will be opportunities for one-on-one meetings during both conferences for interested investors.
4. How can I access the webcasts for these conferences?
The webcasts will be available on the Praxis website under the Events & Presentations section following the events.
5. What platforms does Praxis use for the development of its therapies?
Praxis employs platforms such as Cerebrum™ for small molecules and Solidus™ for antisense oligonucleotides to drive its therapeutic pipeline.
